What Happens When You Stop Tirzepatide: SURMOUNT-4 Explained

What happens when you stop tirzepatide? In SURMOUNT-4, the main randomized trial on this question, most people switched to placebo regained a meaningful share of the weight they had lost within a year. Their blood pressure, cholesterol and blood sugar markers moved back roughly in step with that regain. How much came back varied widely. The trial reports do not describe a withdrawal syndrome, and the trial did not test tapering.

Key takeaways

• SURMOUNT-4 gave everyone tirzepatide for 36 weeks, then randomly switched half of the 670 participants who entered the randomized period, double-blind, to placebo for 52 weeks (JAMA, 2024).
• From week 36 to 88, weight fell another 5.5% on tirzepatide and rose 14.0% on placebo, though the placebo group still ended 9.9% below its starting weight on average (JAMA, 2024).
• In a post hoc analysis, about 82% of placebo participants who had lost at least 10% regained at least a quarter of that loss, and waist, blood pressure, cholesterol and HbA1c moved back further in those who regained more (JAMA Intern Med, 2026).
• The trial reports reviewed here describe no withdrawal syndrome, and the trial did not test tapering.
• SURMOUNT-4 used the manufacturer's brand product, so its results cannot be assumed for compounded tirzepatide, which is not FDA-approved.

What did the SURMOUNT-4 trial test?

SURMOUNT-4 tested whether people who had already lost weight on tirzepatide kept it off better by continuing the drug or by stopping it. It was a phase 3 randomized withdrawal trial run at 70 sites in 4 countries (JAMA, 2024).

In this design, everyone starts on the drug. Then some participants are randomly switched to placebo, an inactive look-alike. "Withdrawal" is a design term that means the drug was taken away. It does not describe symptoms.

1. Lead-in (weeks 0 to 36): 783 adults took tirzepatide open-label, so everyone knew what they were taking.
2. Randomized period (weeks 36 to 88): 670 participants were assigned in equal numbers to continue tirzepatide or switch to placebo. Neither participants nor investigators knew who got which.

Both stages included diet and physical activity guidance. Eligible adults had a body mass index (BMI, weight relative to height) of 30 or more, or 27 or more plus a weight-related health problem. People with diabetes were excluded. The randomized group averaged 48 years of age and 107.3 kg. It was 71% women and 80.1% White, and had lost an average of 20.9% of body weight during the lead-in.

What happens when you stop tirzepatide: weight and appetite

In SURMOUNT-4, people switched to placebo regained a large share of their lost weight over the following year. People who stayed on tirzepatide lost a little more.

The gap between groups in the randomized period was 19.4 percentage points (JAMA, 2024).

Averages hide a wide spread. A post hoc analysis is one designed after the main results rather than specified in advance. One such analysis grouped 308 placebo participants who had lost at least 10% by week 36 by how much of that loss came back (JAMA Intern Med, 2026):

• 54 regained less than 25%.
• 77 regained 25% to under 50%.
• 103 regained 50% to under 75%.
• 74 regained 75% or more.

Regain was common, but it was not uniform. Quality of life followed weight. Stopping was associated with worsening health-related quality of life, and greater regain went with worse patient-reported outcomes (Obesity, 2025).

On appetite, the SURMOUNT-4 reports reviewed here include no hunger measure. A page that gives you a hunger score or a day-by-day timeline is not drawing on this trial. As general context, tirzepatide activates receptors for two gut hormones, GIP and GLP-1. Those receptors influence appetite and slow how quickly food leaves the stomach. When the drug stops, those effects stop too.

Did blood pressure, cholesterol and blood sugar change after stopping?

Yes, on average, and the size of the change tracked how much weight came back. The main paper reported that the placebo group kept a substantial weight reduction, but much of its initial cardiometabolic improvement had been reversed (JAMA, 2024).

The post hoc analysis broke this down by regain group, from week 36 to week 88 (JAMA Intern Med, 2026). Systolic blood pressure is the top number in a reading. Non-HDL cholesterol is total cholesterol minus HDL cholesterol. HbA1c reflects average blood sugar over roughly three months.

Three details matter:

• People who regained less than 25% kept their waist, non-HDL cholesterol and fasting insulin. At week 88, these were not significantly different from week 36.
• Systolic blood pressure still rose in every group.
• Fasting insulin did not rise in a straight line across the groups (-4.0%, +15.4%, +46.2% and +26.3%).

Because people with diabetes were excluded, these HbA1c findings do not describe stopping tirzepatide used for diabetes. The pattern is not unique to tirzepatide. In the STEP 1 extension, most cardiometabolic improvements with semaglutide reverted toward baseline after stopping (Diabetes Obes Metab, 2022).

Is there a withdrawal syndrome when tirzepatide is stopped?

The SURMOUNT-4 publications reviewed here do not describe a withdrawal syndrome. The changes they document after stopping are regain of weight and of cardiometabolic markers.

The most common adverse events were mostly mild to moderate gastrointestinal events. They were more common with tirzepatide than with placebo (JAMA, 2024). After stopping, two things can happen together: gut side effects may ease, and appetite effects fade. Some pages call that combination "withdrawal symptoms." The trial data reviewed here do not support that label.

SURMOUNT-4 also did not test tapering. Placebo replaced the drug under double-blind conditions, with no step-down. Pages calling tapering the best way to stop go beyond this trial.

SURMOUNT-MAINTAIN, published in The Lancet in 2026, compared three approaches after weight reduction:

1. Continuing the maximum tolerated dose.
2. Continuing at a reduced dose.
3. Switching to placebo.

As summarized in published coverage, the maximum tolerated dose maintained the most weight loss. The reduced dose still maintained significantly more weight loss than stopping (Lancet, 2026). That trial tested ongoing maintenance, not a taper to zero. Any change should follow your clinician's guidance and pharmacy instructions.

How SURMOUNT-4 fits with the wider evidence

Other trials and a 2026 meta-analysis point the same way: on average, weight and metabolic markers drift back after weight-management medication stops. Real-world data show much less average regain, which investigators said may reflect that many people restart or switch treatment.

The BMJ review found faster regain after semaglutide or tirzepatide than the overall average across studies (BMJ, 2026). A secondary summary estimated a return to baseline around 1.5 years after stopping these two drugs, compared with about 1.7 years across all included medications. Cardiometabolic markers were projected to drift back in about 1.4 years. Regain was also faster than after behavioral programs. These figures are projections. Mean follow-up after stopping was 32 weeks, and only one included study lasted more than a year.

The Cleveland Clinic figures come from a press release about a study in Diabetes, Obesity and Metabolism. Investigators said restarting or switching treatment may explain the smaller regain. In a trial, people who stop get placebo and nothing else. Real patients change course. Observational data also cannot separate cause from circumstance.

Limits of applying SURMOUNT-4 to everyday patients

SURMOUNT-4 answers one question well in one setting. Several features limit how far it stretches.

• Brand product only. The trial used the manufacturer's tirzepatide, the active ingredient in the FDA-approved brand products Mounjaro and Zepbound, not a compounded preparation. Compounded tirzepatide is not FDA-approved. It has the same active ingredient as Mounjaro and Zepbound (FDA-approved brand products) but is not equivalent to them. See our guide to branded vs compounded GLP-1 options.
• Selected responders. Only people who completed the lead-in were randomized, so the trial studied people who had already tolerated and responded to the drug.
• Narrow population. Diabetes was excluded, and participants were mostly women and mostly White.
• Controlled setting. Stopping was random and blinded, with structured visits and lifestyle guidance. Most people stop for a reason, on their own timing.
• Post hoc design. The cardiometabolic breakdown shows associations, not causes, and covered only people who lost at least 10%. Several authors are affiliated with the company that makes tirzepatide (JAMA Intern Med, 2026).
• One year of follow-up. Longer-term effects remain open, and the BMJ review found little evidence beyond a year.

Before stopping: questions for a clinician and safety screening

Stopping tirzepatide is a legitimate choice. The evidence is there to inform that decision, not to pressure it.

1. Your reason. Side effects, cost, reaching a goal, pregnancy plans or supply problems can each lead to a different plan. For pregnancy and contraception questions, see the tirzepatide and birth control pill interaction.
2. What improved. Ask how weight, waist, blood pressure, cholesterol or blood sugar might be monitored afterward.
3. Your other medications, so they can be reviewed in context.
4. Your options. A clinician may discuss continuing, changing approach, or stopping with a monitoring plan. The Zepbound label pairs the drug with a reduced-calorie diet and increased physical activity (FDA label, 2026).

Safety screening applies to starting and restarting:

• The label carries a boxed warning. Tirzepatide causes thyroid C-cell tumors in rats, and it is unknown whether it causes them in humans, including medullary thyroid carcinoma (MTC), a rare thyroid cancer (FDA label, 2026).
• It is contraindicated with a personal or family history of MTC, or with multiple endocrine neoplasia syndrome type 2 (MEN 2), an inherited condition linked to MTC.
• Acute pancreatitis has been observed with GLP-1 receptor agonists and with Zepbound. The label advises discontinuing if pancreatitis is suspected. Zepbound has not been studied in people with a history of pancreatitis (FDA SPL, 2026).

People with a personal or family history of MTC or MEN 2, or a history of pancreatitis, should not use these medications. A clinician screens for this during intake review. The GLP-1 eligibility checklist covers this screening in detail.

How access works through New Blue

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

1. You complete an asynchronous structured intake, a detailed health questionnaire. Some treatments or states may require a live visit.
2. A licensed clinician reviews it, including the safety screening above, and decides whether treatment is appropriate.
3. If prescribed, a licensed partner pharmacy ships the medication, an injection, directly to you.

Compounded tirzepatide is not FDA-approved. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. Compounded tirzepatide has the same active ingredient as Mounjaro and Zepbound (FDA-approved brand products). Read the compounding disclosure for more.

Availability varies by state. The Tirzepatide GLP-1 pathway ships to every state New Blue Health serves except North Dakota. Check state availability first.

Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work. Consultation timing varies by clinician availability. If treatment isn't appropriate, refunds follow our refund policy. For current pricing, see the Tirzepatide GLP-1 pathway page. This pathway is for adults 21 and older and is not for emergencies.

Frequently Asked Questions

Will I gain all the weight back if I stop tirzepatide?

Not necessarily, but regain is common. In SURMOUNT-4, the placebo group's weight rose 14.0% in the year after stopping, yet the group still ended 9.9% below its starting weight on average. Among 308 placebo participants who had lost at least 10%, 54 regained less than a quarter of that loss, and 74 regained three-quarters or more. Real-world data show smaller average regain, which investigators said may reflect people restarting or switching treatment.

How long after stopping tirzepatide does weight come back?

There is no reliable personal timeline. SURMOUNT-4 followed people for 52 weeks after stopping, and most placebo participants who had lost at least 10% regained at least a quarter of that loss in that window. The 2026 BMJ meta-analysis found faster average regain after semaglutide or tirzepatide than the overall average across weight-management medications. Few included studies followed people beyond a year.

Does stopping tirzepatide cause withdrawal symptoms?

The SURMOUNT-4 publications reviewed here do not describe a withdrawal syndrome. The documented changes after stopping were regain of weight and of markers such as waist size, blood pressure and cholesterol. Easing gut side effects plus returning appetite is sometimes mislabeled as "withdrawal."

Should I taper off tirzepatide instead of stopping all at once?

SURMOUNT-4 did not test tapering, so it cannot say whether tapering changes regain. SURMOUNT-MAINTAIN found a reduced dose maintained more weight loss than placebo, but that was ongoing maintenance, not a taper. How to stop is a decision to make with a licensed clinician, following your clinician's guidance and pharmacy instructions.

Does SURMOUNT-4 apply to compounded tirzepatide?

No. SURMOUNT-4 studied the manufacturer's brand product, not a compounded preparation. Compounded tirzepatide is not FDA-approved. It has the same active ingredient as Mounjaro and Zepbound (FDA-approved brand products), but brand-trial results cannot be assumed for it.

Can I restart tirzepatide later?

Restarting is a clinical decision, not an automatic one. A licensed clinician reviews your current health, history and goals before deciding whether it is appropriate. The same screening for MTC, MEN 2 and pancreatitis applies again.

Who should not use tirzepatide?

People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), or a history of pancreatitis, should not use tirzepatide or other GLP-1 medications. The Zepbound label also lists known serious hypersensitivity to tirzepatide or its ingredients as a contraindication. A clinician screens for these during intake review.

Sources

1. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024. https://pubmed.ncbi.nlm.nih.gov/38078870/
2. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Internal Medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/41284285/
3. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, 2026. https://pubmed.ncbi.nlm.nih.gov/41500720/
4. ZEPBOUND (tirzepatide) injection, Highlights of Prescribing Information. U.S. Food and Drug Administration, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf
5. ZEPBOUND (tirzepatide) Injection, structured product label. U.S. Food and Drug Administration, 2026. https://www.accessdata.fda.gov/spl/data/1761b768-7da0-44a9-bded-54c3bc63414a/1761b768-7da0-44a9-bded-54c3bc63414a.xml
6. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/
7. What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights. Cleveland Clinic Newsroom, 2026. https://newsroom.clevelandclinic.org/2026/03/12/what-happens-when-patients-stop-taking-glp-1-drugs-new-cleveland-clinic-study-reveals-real-world-insights
8. Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4. Obesity, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12559773/
9. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 2026. https://pubmed.ncbi.nlm.nih.gov/42119587/

Medical disclaimer: This article is educational and is not medical advice. Treatment decisions, including whether to start, continue or stop tirzepatide, are made by a licensed clinician based on your individual health history. New Blue Health is a technology and administrative services platform, not a medical provider.